MA32081B1 - Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancer - Google Patents
Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancerInfo
- Publication number
- MA32081B1 MA32081B1 MA33089A MA33089A MA32081B1 MA 32081 B1 MA32081 B1 MA 32081B1 MA 33089 A MA33089 A MA 33089A MA 33089 A MA33089 A MA 33089A MA 32081 B1 MA32081 B1 MA 32081B1
- Authority
- MA
- Morocco
- Prior art keywords
- quinazolines
- dialkoxyquinazoline
- surprisingly
- class
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compte tenu du potentiel important offert par la classe de composés formés par les quinazolines, la synthèse et le criblage d'un grand nombre de nouvelles entités chimiques à nouvelles caractéristiques structurales a été entreprise. De façon surprenante et inattendue, il a été prouvé que les quinazolines ayant un groupe 3- éthynylanilino en position 4 et des groupes alcoxy substitués de façon spécifique dans les positions 6 et 7 confèrent propriétés antiprolifératives très améliorées et spéciales par rapport à d'autres éléments importants de la classe de médicaments formée par les quinazolines. Egalement, de façon surprenante, les composés de cette invention sont bien moins toxiques et le profil d'innocuité est extrêmement avantageux pour les applications thérapeutiques. Les nouvelles entités chimiques décrites dans cette invention sont représentées par la structure générale (i) et n'ont jamais été synthétisées ou étudiées pour leurs avantages thérapeutiques et leur profil d'innocuité. Le composé (i) est le nrc-2694, de structure (a).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2008/000036 WO2009090661A1 (fr) | 2008-01-18 | 2008-01-18 | Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32081B1 true MA32081B1 (fr) | 2011-02-01 |
Family
ID=39769348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33089A MA32081B1 (fr) | 2008-01-18 | 2010-08-13 | Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancer |
Country Status (27)
Country | Link |
---|---|
US (5) | US8143250B2 (fr) |
EP (2) | EP2229369B1 (fr) |
JP (1) | JP2011509995A (fr) |
KR (2) | KR101640161B1 (fr) |
CN (1) | CN101918374A (fr) |
AP (1) | AP2886A (fr) |
AU (1) | AU2008347940A1 (fr) |
BR (1) | BRPI0822012A2 (fr) |
CA (1) | CA2711737C (fr) |
CY (1) | CY1118193T1 (fr) |
DK (2) | DK3012251T3 (fr) |
EA (1) | EA018514B1 (fr) |
ES (2) | ES2642159T3 (fr) |
HR (1) | HRP20161522T1 (fr) |
HU (1) | HUE030640T2 (fr) |
IL (1) | IL207046A (fr) |
LT (1) | LT2229369T (fr) |
MA (1) | MA32081B1 (fr) |
MX (1) | MX2010007852A (fr) |
NZ (1) | NZ586946A (fr) |
PL (1) | PL2229369T3 (fr) |
PT (1) | PT2229369T (fr) |
SG (1) | SG187490A1 (fr) |
SI (1) | SI2229369T1 (fr) |
UA (1) | UA101010C2 (fr) |
WO (1) | WO2009090661A1 (fr) |
ZA (1) | ZA201005116B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101640161B1 (ko) * | 2008-01-18 | 2016-07-15 | 낫코 파마 리미티드 | 암과 관련된 질환의 치료에 유용한 6,7-디알콕시 퀴나졸린 유도체 |
US9050341B2 (en) * | 2009-07-14 | 2015-06-09 | Natco Pharma Limited | Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives |
CN101857618B (zh) * | 2010-06-13 | 2015-11-25 | 中国海洋大学 | 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物,其制备方法和应用 |
US9388160B2 (en) * | 2011-10-12 | 2016-07-12 | Teligene Ltd | Quinazoline derivatives as kinases inhibitors and methods of use thereof |
AR092289A1 (es) * | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
CN103172641B (zh) * | 2011-12-20 | 2014-06-11 | 钱卫 | 杂环胺基烷氧基取代的喹唑啉衍生物及其用途 |
WO2013142817A2 (fr) | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions et procédés d'amélioration du bénéfice thérapeutique de l'indirubine et de ses analogues y compris du mésoindigo |
WO2015077375A1 (fr) | 2013-11-20 | 2015-05-28 | Signalchem Lifesciences Corp. | Dérivés de quinazoline servant d'inhibiteurs des kinases de la famille tam |
WO2017062500A2 (fr) | 2015-10-05 | 2017-04-13 | The Trustees Of Columbia University In The City Of New York | Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies |
ES2899145T3 (es) | 2017-04-15 | 2022-03-10 | Natco Pharma Ltd | Un proceso mejorado para la preparación de diclorhidrato de N-(3-etinilfenil)-7-metoxi-6-(3-morfolinopropoxi)quinazolin-4-amina |
CN111499577A (zh) * | 2019-01-30 | 2020-08-07 | 华东师范大学 | 邻二苯基取代五元含氮芳杂环类类化合物及其应用 |
GB202108302D0 (en) * | 2021-06-10 | 2021-07-28 | Natco Pharma Ltd | New treatment |
IL309181A (en) | 2021-06-10 | 2024-02-01 | Natco Pharma Ltd | EGFR inhibitor for the treatment of head and neck cancer |
CN115518071B (zh) * | 2021-06-24 | 2024-03-19 | 中国人民解放军联勤保障部队第九〇一医院 | 一种化合物在制备抗食管癌的药物中的应用 |
WO2024121861A1 (fr) * | 2022-12-08 | 2024-06-13 | Natco Pharma Limited | Inhibiteur d'egfr pour traiter le cancer de la tête et du cou |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US690221A (en) | 1901-06-20 | 1901-12-31 | Frederik Christian Viggo Arp | Stand for cycles. |
US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
JP3088018B2 (ja) | 1995-03-30 | 2000-09-18 | ファイザー・インコーポレーテッド | キナゾリン誘導体 |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6706721B1 (en) * | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
WO2005070909A1 (fr) | 2004-01-22 | 2005-08-04 | Natco Pharma Limited | Procede ameliore de preparation de gefitinib |
WO2006090413A1 (fr) | 2005-02-23 | 2006-08-31 | Natco Pharma Limited | Nouvelle forme cristalline de gefitinib et son procede de preparation |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7960545B2 (en) | 2005-11-23 | 2011-06-14 | Natco Pharma Limited | Process for the prepartion of erlotinib |
KR101640161B1 (ko) * | 2008-01-18 | 2016-07-15 | 낫코 파마 리미티드 | 암과 관련된 질환의 치료에 유용한 6,7-디알콕시 퀴나졸린 유도체 |
-
2008
- 2008-01-18 KR KR1020107015858A patent/KR101640161B1/ko active IP Right Grant
- 2008-01-18 BR BRPI0822012-3A patent/BRPI0822012A2/pt not_active Application Discontinuation
- 2008-01-18 AU AU2008347940A patent/AU2008347940A1/en not_active Abandoned
- 2008-01-18 JP JP2010542740A patent/JP2011509995A/ja active Pending
- 2008-01-18 PT PT87200994T patent/PT2229369T/pt unknown
- 2008-01-18 CN CN2008801248191A patent/CN101918374A/zh active Pending
- 2008-01-18 EA EA201001173A patent/EA018514B1/ru unknown
- 2008-01-18 EP EP08720099.4A patent/EP2229369B1/fr active Active
- 2008-01-18 PL PL08720099T patent/PL2229369T3/pl unknown
- 2008-01-18 US US12/812,726 patent/US8143250B2/en active Active
- 2008-01-18 HU HUE08720099A patent/HUE030640T2/en unknown
- 2008-01-18 DK DK15199926.5T patent/DK3012251T3/en active
- 2008-01-18 ES ES15199926.5T patent/ES2642159T3/es active Active
- 2008-01-18 UA UAA201010197A patent/UA101010C2/ru unknown
- 2008-01-18 ES ES08720099.4T patent/ES2593321T3/es active Active
- 2008-01-18 WO PCT/IN2008/000036 patent/WO2009090661A1/fr active Application Filing
- 2008-01-18 LT LTEP08720099.4T patent/LT2229369T/lt unknown
- 2008-01-18 NZ NZ586946A patent/NZ586946A/en unknown
- 2008-01-18 DK DK08720099.4T patent/DK2229369T3/en active
- 2008-01-18 KR KR1020167018317A patent/KR101762306B1/ko active IP Right Grant
- 2008-01-18 SG SG2013004064A patent/SG187490A1/en unknown
- 2008-01-18 CA CA2711737A patent/CA2711737C/fr active Active
- 2008-01-18 EP EP15199926.5A patent/EP3012251B1/fr active Active
- 2008-01-18 AP AP2010005357A patent/AP2886A/xx active
- 2008-01-18 MX MX2010007852A patent/MX2010007852A/es active IP Right Grant
- 2008-01-18 SI SI200831672A patent/SI2229369T1/sl unknown
-
2010
- 2010-07-09 US US12/833,789 patent/US8921362B2/en active Active
- 2010-07-15 IL IL207046A patent/IL207046A/en active IP Right Grant
- 2010-07-19 ZA ZA2010/05116A patent/ZA201005116B/en unknown
- 2010-08-13 MA MA33089A patent/MA32081B1/fr unknown
-
2014
- 2014-12-26 US US14/583,286 patent/US9481655B2/en active Active
-
2016
- 2016-09-16 CY CY20161100921T patent/CY1118193T1/el unknown
- 2016-10-05 US US15/286,464 patent/US20170079983A1/en not_active Abandoned
- 2016-11-17 HR HRP20161522TT patent/HRP20161522T1/hr unknown
-
2019
- 2019-03-11 US US16/298,944 patent/US20190201408A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32081B1 (fr) | Dérivés de 6,7-dialcoxyquinazoline utiles pour traiter des troubles apparentés au cancer | |
MA32120B1 (fr) | Nouveaux composes chimiques | |
MA29289B1 (fr) | Composes bis aryles et heteroaryles substitues en tant qu'antagonistes selectifs de 5ht2a | |
TW200634016A (en) | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | |
Ali et al. | Synthesis of isatin thiosemicarbazones derivatives: In vitro anti-cancer, DNA binding and cleavage activities | |
BR0314721A (pt) | Compostos tricìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo-os | |
MA27725A1 (fr) | Benzopyrannes utiles pour le traitement d'etats inflammatoires | |
MA45153B1 (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
Ali et al. | Synthesis of copper (II) complexes of isatin thiosemicarbazone derivatives: In vitro anti-cancer, DNA binding, and cleavage activities | |
MA27909A1 (fr) | Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents | |
CA2446756A1 (fr) | Composes de thiazole inhibiteurs des proteines kinase | |
EA200800975A1 (ru) | ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ | |
TW200633982A (en) | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors | |
MA30289B1 (fr) | Dérivés d'amines | |
DE69919707D1 (de) | Glycogen synthase kinase 3 inhibitoren | |
MA27926A1 (fr) | Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1 | |
HUE031997T2 (en) | Dihydrate of benzothiophene compound and process | |
EA017914B8 (ru) | 1,4-ДВУЗАМЕЩЕННЫЕ 3-ЦИАНОПИРИДОНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЗИТИВНЫХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 | |
MA38069A1 (fr) | Composés hétéroaromatiques utilisés comme ligands de la dopamine d1 | |
TW200502221A (en) | Novel lactams and uses thereof | |
FI924397A (fi) | Substituerade pyrimidiner | |
MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
JP2006514922A (ja) | アルツハイマー病を治療するための、二重結合部位アセチルコリンエステラーゼ阻害剤 | |
NO20050714L (no) | Nye forbindelser | |
MA29566B1 (fr) | Composes chimiques |